https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34787 Wed 19 Jan 2022 15:18:05 AEDT ]]> Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1β https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27569 Wed 11 Apr 2018 11:56:33 AEST ]]> Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: a position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34064 Wed 04 Sep 2019 10:06:34 AEST ]]> Reduced antiviral interferon production in poorly controlled asthma is associated with neutrophilic inflammation and high-dose inhaled corticosteroids https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26090 Wed 02 Mar 2022 14:26:24 AEDT ]]> Efficacy of azithromycin in severe asthma from the AMAZES randomised trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37078 Tue 29 Sep 2020 11:48:51 AEST ]]> Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47085 Tue 13 Dec 2022 16:35:23 AEDT ]]> Biomarker signatures for progressive idiopathic pulmonary fibrosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47057 Tue 13 Dec 2022 15:32:32 AEDT ]]> Circulating RNA differences between patients with stable and progressive idiopathic pulmonary fibrosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38777 Tue 08 Feb 2022 12:17:52 AEDT ]]> Gastroesophageal reflux and antacid therapy in IPF: Analysis from the Australia IPF Registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46902 8. Overall, there was no difference in survival or disease progression, regardless of antacid treatment, GORD diagnosis or GORD symptoms. Conclusions: Neither the use of antacid therapy nor the presence of GORD symptoms affects longer term outcomes in IPF patients. This contributes to the increasing evidence that antacid therapy may not be beneficial in IPF patients and that GORD directed therapy should be considered on an individual basis to treat the symptoms of reflux.]]> Tue 06 Dec 2022 16:07:24 AEDT ]]> Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46906 Tue 06 Dec 2022 16:07:23 AEDT ]]> Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54560 Thu 29 Feb 2024 10:27:50 AEDT ]]> A sputum 6-gene signature predicts future exacerbations of poorly controlled asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36051 Thu 28 Oct 2021 13:04:53 AEDT ]]> Airway dysbiosis: Haemophilus influenza and Tropheryma in poorly controlled asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24324 Tropheryma whipplei and Haemophilus influenzae in sputum. Adults with neutrophilic asthma had reduced bacterial diversity and species richness. Tropheryma was identified and confirmed with real-time PCR in 12 (40%) participants. Haemophilus occurred most often in a group of younger atopic males with an increased proportion of neutrophils. PCR confirmed the presence of H. influenzae in 35 (76%) participants with poorly controlled asthma. There are phenotype-specific alterations to the airway microbiome in asthma. Reduced bacterial diversity combined with a high prevalence of H. influenzae was observed in neutrophilic asthma, whereas eosinophilic asthma had abundant T. whipplei.]]> Thu 28 Oct 2021 13:02:17 AEDT ]]> Periostin levels and eosinophilic inflammation in poorly-controlled asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24852 Thu 17 Feb 2022 09:28:28 AEDT ]]> Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49306 Thu 11 May 2023 14:32:33 AEST ]]> Long-Term Azithromycin reduces haemophilus influenzae and increases antibiotic resistance in severe asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47850 Thu 02 Feb 2023 16:46:49 AEDT ]]> Altered sputum granzyme B and granzyme B/proteinase inhibitor-9 in patients with non-eosinophilic asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21345 n = 10), and patients with NEA (n = 22) or eosinophilic asthma (EA) (n = 15) using flow cytometry. Results: Granzyme B expression and the ratio of granzyme B to PI-9 positive cells were highest in those with NEA for both CD3+ and CD4+ T cells. The expression of granzyme B was not statistically different between patients with NEA and EA; however, the ratio of granzyme B to PI-9 positive cells for CD3+ T cells was significantly higher in those with NEA compared with EA. Conclusions: Induced sputum provides a non-invasive tool for investigating T cell cytotoxic mediators in the various asthma subtypes. Granzyme B expression is increased in NEA and the contribution of granzyme B to chronic inflammation requires further study.]]> Sat 24 Mar 2018 07:51:24 AEDT ]]> Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33089 Fri 24 Aug 2018 16:46:54 AEST ]]> Mepolizumab effectiveness and identification of super-responders in severe asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40118 Fri 22 Jul 2022 13:48:23 AEST ]]> The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46066 Fri 11 Nov 2022 14:45:17 AEDT ]]> Treatable traits can be identified in a severe asthma registry and predict future exacerbations https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37892 Fri 01 Apr 2022 09:25:28 AEDT ]]>